XBiotech Inc. (XBIT) is a pioneering biopharmaceutical company that is poised to lead in the exciting and rapidly evolving field of true human therapeutic antibodies. Based out of Austin, Texas, the company trades on the Nasdaq under the ticker symbol XBIT. Known for developing innovative technologies for researching and manufacturing these groundbreaking therapeutics, XBiotech's main focus is on the discovery and clinical development of its proprietary product candidates that can treat a wide range of diseases.
Notably, one of XBiotech's core technologies is the groundbreaking True Human™ technology, which allows for the discovery and production of therapeutic antibodies naturally occurring in the human species. Such a technology, capable of harnessing the human immune response, represents a profound leap in medical science that could potentially revolutionize the way we treat many diseases.
XBiotech Inc. has a robust pipeline of potential therapies in various stages of development aimed at providing treatments for numerous indications, such as cancer, cardiovascular disease, dermatological conditions, and infectious diseases. The company has gained particular attention for its lead product, bermekimab, which is currently in multiple phase II clinical trials for diseases, including atopic dermatitis, hidradentis suppurativa, and COVID-19 symptoms.
Committed to pioneering the next generation of therapeutic antibodies, XBiotech is driven by its mission to improve the quality of human life using advanced antibody therapeutics. The firm's value is underpinned by a strong intellectual property portfolio, ensuring its ability to protect its innovations and technologies successfully.
Despite its relatively modest size compared to some of the behemoth pharmaceutical firms, XBiotech is not short on ambition or innovation. The same dedication to innovation extends beyond product development to manufacturing. XBiotech has designed and built a state-of-the-art, proprietary manufacturing facility to efficiently produce its therapeutic antibodies.
Overall, XBiotech Inc. stands as an extraordinary venture that has the potential to make significant contributions to the medical community and the patients it serves. It represents a hopeful future that emphasizes the power and necessity of continuous innovation and research in both therapeutics and technology. Its commitment to finding new treatments for diseases and making them readily accessible could effectively impact global healthcare.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
John Simard, Founder & Chairman of XBiotech Inc., recently purchased US$711k worth of the company's stock at an average price of US$1.93, increasing his holding by 9.6%. This marks the largest insider purchase in the last year, indicating optimism about the company's current valuation, despite XBiotech reporting a loss in the past year. Insiders collectively own 38% of the company, valued at approximately US$23 million.
XBiotech (NASDAQ:XBIT) Director John Simard recently purchased 368,524 shares of the company's stock for over $711,000, increasing his total holdings to 4,191,690 shares valued at over $8 million. The biopharmaceutical company's stock traded up on Wednesday, despite missing analyst earnings estimates in its last report, and has received a "Sell" rating from analysts, though Weiss Ratings recently upgraded it from "sell (e+)" to "sell (d-)". Institutional investors have also been adjusting their positions in XBiotech.